Experimental and Molecular Pathology Laboratory
- Markus Kaller, Dr. rer. nat
- Matjaz Rokavec, Dr. rer. nat.
- Markus Winter, Dr. rer. nat. , Tel.: 089 2180 73733
- Nassim Bouznad, PhD, Dr. med. vet.
- Stephanie Jaeckel, Dr. rer. nat
- Ursula Götz, BTA, research assistent
- Janine König, M.Sc. Biology, Dr. rer. nat. student
- Jinjiang Chou, M.Sc. (Biochemistry and Molecular Biology), Dr. rer. nat. student
- Fangteng Liu, M.Sc. (Medicine), Dr. hum. biol. student
- Zekai Huang, M.Sc. (Medicine), PhD student/Student, Tel.: 089 2180 73734
- Wenjing Shi, M.Sc. (Medicine), PhD student/Studentin, Tel.: 089 2180 73625
- Chunfeng Liu, M.Sc. (Pharmacy), PhD student/Stundentin, Tel.: 089 2180 73625
Human tumors result from changes in specific genes. We are mainly interested in the function of two genes, c-MYC and p53, which are commonly altered in human cancer, and their downstream effectors. c-MYC represents a proto-oncogene, whereas p53 is a tumor suppressor gene. Both genes encode transcription factors, which bind to DNA in a sequence-specific manner. By activating a number of target genes, which encode proteins or microRNAs, c-MYC and p53 regulate cell cycle progression/proliferation, apoptosis and senescence in an antagonistic manner. Interestingly, the p53 pathway represents a fail-safe mechanism against c-MYC-driven proliferation by mediating apoptosis (Hermeking and Eick, 1994). Furthermore, c-MYC antagonizes the antiproliferative activity of p53 (Hermeking et al., 1995; Jung et al., 2008). We have characterized several genes and microRNAs directly regulated by c-MYC and p53 in detail (Hermeking et al. 1997, 2000; Menssen and Hermeking, 2002; Tarasov et al., 2007; Jung et al., 2008).
Interestingly, some of the genes induced by p53 are themselves inactivated in cancer. E.g. 14-3-3sigma and miR-34a are silenced by CpG methylation in a number of tumor types (Lodygin et al., 2003, 2004, 2005, 2008). Detection of these events in DNA released from tumor cells may have tumor diagnostic potential.
We are currently characterizing p53- and c-MYC-regulated pathways by multiple different approaches and technologies. Among these are SAGE, microarray analyses, parallel sequencing, quantitative PCR, ChIP, methylation-specific PCR, lasermicrodissection, proteomics (TAP-tagging/MudPIT), live cell imaging/laserscanning microscopy, FACS and the generation/analysis of mouse knock-out models.
The miR-34 gene family as mediator of tumor suppression by p53
Figure modified from Hermeking, H. (2007) p53 enters the microRNA world. Cancer Cell 12, 414-418; Hermeking, H. (2009) The miR-34 family in cancer and apoptosis. Cell Death & Differentiation, May 22. [Epub ahead of print] PMID: 19461653); Kaller et al. (2011) MCP 10(8):M111.010462